FTY720 Attenuates LPS-Induced Inflammatory Bone Loss by Inhibiting Osteoclastogenesis via the NF-κB and HDAC4/ATF Pathways
Open Access
- 6 January 2023
- journal article
- research article
- Published by Wiley in Journal of Immunology Research
- Vol. 2023, 1-14
Abstract
Osteoclast (OC) abnormalities lead to many osteolytic diseases, such as osteoporosis, inflammatory bone erosion, and tumor-induced osteolysis. Exploring effective strategies to remediate OCs dysregulation is essential. FTY720, also known as fingolimod, has been approved for the treatment of multiple sclerosis and has anti-inflammatory and immunosuppressive effects. Here, we found that FTY720 inhibited osteoclastogenesis and OC function by inhibiting nuclear factor kappa-B (NF-κB) signaling. Interestingly, we also found that FTY720 inhibited osteoclastogenesis by upregulating histone deacetylase 4 (HDAC4) expression levels and downregulating activating transcription factor 4 (ATF4) expression levels. In vivo, FTY720 treatment prevented lipopolysaccharide- (LPS-) induced calvarial osteolysis and significantly reduced the number of tartrate-resistant acid phosphatase- (TRAP-) positive OCs. Taken together, these results demonstrate that FTY720 can inhibit osteoclastogenesis and ameliorate inflammation-induced bone loss. Which may provide evidence of a new therapeutic target for skeletal diseases caused by OC abnormalities.Keywords
Funding Information
- Natural Science Foundation of Shanxi Province (20210302123284, 201701D121170, 2017-063, 81871815)
- Shanxi Scholarship Council of China (20210302123284, 201701D121170, 2017-063, 81871815)
- National Natural Science Foundation of China (20210302123284, 201701D121170, 2017-063, 81871815)
This publication has 59 references indexed in Scilit:
- RANKL induces NFATc1 acetylation and stability via histone acetyltransferases during osteoclast differentiationBiochemical Journal, 2011
- Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosisNature Reviews Drug Discovery, 2010
- Activating transcription factor 4 regulates osteoclast differentiation in miceJournal of Clinical Investigation, 2010
- Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasisNature, 2009
- NF-κB modulators in osteolytic bone diseasesCytokine & Growth Factor Reviews, 2009
- NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubismJournal of Clinical Investigation, 2008
- NF‐κB activation in development and progression of cancerCancer Science, 2007
- Autoamplification of NFATc1 expression determines its essential role in bone homeostasisJournal of Experimental Medicine, 2005
- Sesquiterpene Lactone Parthenolide Blocks Lipopolysaccharide-Induced Osteolysis Through the Suppression of NF-κB ActivityJournal of Bone and Mineral Research, 2004
- Osteoclast differentiation and activationNature, 2003